Company Overview and News

 
Tencent, Cnooc to Join Hang Seng China Index in Major Revamp - Bloomberg

2018-02-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
There’s a Good Chance Your Favorite Clothes Are Made by a Company You've Never Heard Of - Bloomberg

2017-11-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
As China Takes Center Stage In The World, It May Be Time To Buy Chinese Stocks

2017-11-14 forbes
China's President Xi Jinping raises a toast at a State Banquet to welcome him in Hanoi, Vietnam Sunday, Nov. 12, 2017. (Kham/Pool photo via AP)

 
Search is on for top business talent in Hong Kong

2017-06-06 scmp
The longest-running and most recognised business awards programme in Hong Kong, the DHL/SCMP Hong Kong Business Awards kicked off its 2017 campaign on Monday.

1
Who are the richest of the rich?

2017-02-22 smh.com.au
Sitting at a table, grinding his pinkie into the corner of his mouth and staring at the screen, Dr Evil announces he is holding the world ransom for $1 million. Having been cryogenically frozen for 30 years, the comic villain created by the actor Mike Myers is shocked when he is told that $1 million isn't a lot of money in 1997.

 
Who are the richest of the rich?

2017-02-22 theage.com.au
Sitting at a table, grinding his pinkie into the corner of his mouth and staring at the screen, Dr Evil announces he is holding the world ransom for $1 million. Having been cryogenically frozen for 30 years, the comic villain created by the actor Mike Myers is shocked when he is told that $1 million isn't a lot of money in 1997.

 
Where the world’s wealthiest invest their billions

2017-02-21 theage.com.au
At the threshold of $US1 billion, a 5 per cent return would yield an annual interest payment of $US50 million ($65 million) - without ever touching the principal.

1
Where the world’s wealthiest invest their billions

2017-02-21 smh.com.au
At the threshold of $US1 billion, a 5 per cent return would yield an annual interest payment of $US50 million ($65 million) - without ever touching the principal.

 
Vietnamese Factories Hum at Full Capacity Despite Trump Snub - Bloomberg

2017-01-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Prada found wanting in assessment of forced labour safeguards | Global development | The Guardian

2016-12-08 theguardian
Ralph Lauren and Hugo Boss also perform modestly in study of quality and transparency of efforts by leading fashion firms to protect against forced labour

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

8h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

8h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

18h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...